Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 1190.2 g/mol |
---|---|
Molecular Formula | C57H64FN13O15 |
Hydrogen Bond Donor Count | 10 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 14 |
Exact Mass | 1189.46288655 g/mol |
Monoisotopic Mass | 1189.46288655 g/mol |
Topological Polar Surface Area | 386 A^2 |
Heavy Atom Count | 86 |
Formal Charge | 0 |
Complexity | 2310 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Registration Number : 301MF10063
Registrant's Address : Zone industriale de l'Auriettaz, Rue de l'Auriette 151, 1170 Aubonne, Switzerland
Initial Date of Registration : 2019-09-11
Latest Date of Registration : 2020-08-05
Registration Number : 305MF10129
Registrant's Address : Zone industriale de l'Auriettaz, Rue de l'Auriette 151, 1170 Aubonne, Switzerland
Initial Date of Registration : 2023-12-06
Latest Date of Registration : 2023-12-06
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
Details:
TTX-080 is a novel, first-in-class antibody targeting HLA-G. Patients with biomarker-defined metastatic colorectal cancer (mCRC) in combination with cetuximab and FOLFIRI.
Lead Product(s): TTX-080,Cetuximab
Therapeutic Area: Oncology Brand Name: TTX-080
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2024
Tizona Expands Phase 1b Trial of TTX-080 with EGFR Inhibitor in Colorectal Cancer
Details : TTX-080 is a novel, first-in-class antibody targeting HLA-G. Patients with biomarker-defined metastatic colorectal cancer (mCRC) in combination with cetuximab and FOLFIRI.
Brand Name : TTX-080
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 31, 2024
Details:
The collaboration aims to evaluate BND-35 in combination with Merck's anti-EGFR monoclonal antibody Erbitux (cetuximab) in a Phase 1 for unresectable or metastatic solid tumors.
Lead Product(s): BND-35,Cetuximab
Therapeutic Area: Oncology Brand Name: BND-35
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2024
Lead Product(s) : BND-35,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Biond Biologics And Merck Partner on BND-35 Trial for Solid Tumors
Details : The collaboration aims to evaluate BND-35 in combination with Merck's anti-EGFR monoclonal antibody Erbitux (cetuximab) in a Phase 1 for unresectable or metastatic solid tumors.
Brand Name : BND-35
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 29, 2024
Details:
QTX3046, a novel orally bioavailable, brain-penetrant, non-covalent allosteric KRASG12D inhibitor has announced dosing of first patient in Phase 1/1b trail for the treatment of advanced solid tumors.
Lead Product(s): QTX3046,Cetuximab
Therapeutic Area: Oncology Brand Name: QTX3046
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Quanta Doses First Patient in Phase 1/1b Trial of QTX3046 and Other Updates
Details : QTX3046, a novel orally bioavailable, brain-penetrant, non-covalent allosteric KRASG12D inhibitor has announced dosing of first patient in Phase 1/1b trail for the treatment of advanced solid tumors.
Brand Name : QTX3046
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2024
Details:
Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
Lead Product(s): Cetuximab,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Enlituo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Cetuximab,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
Details : Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
Brand Name : Enlituo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab
Therapeutic Area: Oncology Brand Name: Krazati
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2024
Bristol Myers Squibb Announces FDA Approval of KRAZATI with Cetuximab for CRC
Details : KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.
Brand Name : Krazati
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2024
Details:
KRAZATI (adagrasib), a selective oral inhibitor of KRASG12C, is being evaluated with cetuximab for KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab
Therapeutic Area: Oncology Brand Name: Krazati
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Lead Product(s) : Adagrasib,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KRAZATI-Cetuximab Shows Activity for KRAS G12C-Mutated Metastatic Colorectal Cancer
Details : KRAZATI (adagrasib), a selective oral inhibitor of KRASG12C, is being evaluated with cetuximab for KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Brand Name : Krazati
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2024
Details:
PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Lead Product(s): Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area: Oncology Brand Name: PCM-075
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Lead Product(s) : Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cardiff Provides Update on Phase 2 ONSEMBLE Trial in Patients with RAS-Mutated mCRC
Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Brand Name : PCM-075
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 29, 2024
Details:
PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Lead Product(s): Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area: Oncology Brand Name: PCM-075
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Lead Product(s) : Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cardiff Doses First Patient in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial
Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Brand Name : PCM-075
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 29, 2024
Details:
Krazati (adagrasib) is a selective KRAS G12C inhibitor under evaluation for KRAS G12C-mutated metastatic colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab,BMS-986466
Therapeutic Area: Oncology Brand Name: Krazati
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Lead Product(s) : Adagrasib,Cetuximab,BMS-986466
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Accepts KRAZATI® Supplemental NDA for KRAS G12C-Mutated Cancer Treatment
Details : Krazati (adagrasib) is a selective KRAS G12C inhibitor under evaluation for KRAS G12C-mutated metastatic colorectal cancer.
Brand Name : Krazati
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2024
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Brand Name: NBTXR3
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies LLC
Deal Size: $34.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 07, 2023
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies LLC
Deal Size : $34.7 million
Deal Type : Public Offering
NANOBIOTIX Announces Closing of Global Offering
Details : The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head...
Brand Name : NBTXR3
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 07, 2023
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Cetuximab manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cetuximab, including repackagers and relabelers. The FDA regulates Cetuximab manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cetuximab API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cetuximab manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cetuximab supplier is an individual or a company that provides Cetuximab active pharmaceutical ingredient (API) or Cetuximab finished formulations upon request. The Cetuximab suppliers may include Cetuximab API manufacturers, exporters, distributors and traders.
click here to find a list of Cetuximab suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cetuximab Drug Master File in Japan (Cetuximab JDMF) empowers Cetuximab API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cetuximab JDMF during the approval evaluation for pharmaceutical products. At the time of Cetuximab JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cetuximab suppliers with JDMF on PharmaCompass.
Cetuximab Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cetuximab GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cetuximab GMP manufacturer or Cetuximab GMP API supplier for your needs.
A Cetuximab CoA (Certificate of Analysis) is a formal document that attests to Cetuximab's compliance with Cetuximab specifications and serves as a tool for batch-level quality control.
Cetuximab CoA mostly includes findings from lab analyses of a specific batch. For each Cetuximab CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cetuximab may be tested according to a variety of international standards, such as European Pharmacopoeia (Cetuximab EP), Cetuximab JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cetuximab USP).
LOOKING FOR A SUPPLIER?